



International HCC Symposium presented by AASLD, EASL & ISVHLD



General Session

Hashem El Serag	Global epidemiology of HCC in the 21st Century: Changing etiology of liver disease
Thomas Baumert	Pathogenesis of HCC: Genetic and epigenetic factors
Morris Sherman	HCC surveillance: How, When and What to do with a positive result
David Kaplan	Strategies to improve Healthcare delivery for HCC: A Multidisciplinary approach

Hepatitis B and HCC

Massimo Levrero	Oncogenesis of HBV-related HCC – virus vs. inflammation
Lewis Roberts	Epidemiology of HBV-related HCC – continental perspectives
George Papatheordides	Assessing HCC risk in Hepatitis B: How to use different scoring systems
Ray Kim	Development of HCC in patients with suppressed viral replication: Changes in risk over time

Hepatitis C and HCC

Norah Terrault	Assessing HCC risk: who should undergo surveillance (this would include post SVR)
Greg Dore	Does the presence of HCC alter the response to HCV treatment
Antonio Craxi	Recurrence of HCC after Therapy for HCV: Fact or Fiction.
Xavier Forns	Liver transplantation for HCC in hepatitis C: What are the issues

NOHep Village presented by the WHA

NOHep is a global movement aimed at uniting people from across the world to take action, to speak out and be engaged to ensure viral hepatitis is eliminated by 2030.



Abstracts published in the
Journal of Viral Hepatitis

Abstract Submission Guidelines

Abstract Submissions Open: October 2017

Abstract Submission Close: February 12, 2018

Late-Breaking Abstract Submission Opens: March 1, 2018

Late-Breaking Abstract Submission Closes: March 30, 2018

Oral Communications

Authors are invited to submit abstracts, classified by topics. Submitted abstracts will be reviewed by the Local Organising Committee and chosen for oral presentations of 10-15 minutes.

Posters

Authors are invited to present their new research findings or important ongoing research as posters related to one of the given abstract topics on the next panel.

Abstract Submission

Abstracts must be submitted via the website:
<http://www.globalhepatitisummit2018.com/abstracts>

The Congress secretariat is not able to accept abstracts submitted via email or fax.

When submitting your abstract please follow the instructions listed on the website.

Abstract Topics

Basic Science

- a) Viral Hepatitis
 - I. Hepatitis B
 - II. Hepatitis C
 - III. Other Hepatitis Viruses
- b) Animal and Tissue Culture Models
- c) Fibrogenesis and Inflammation

Clinical

- a) Viral Hepatitis
 - I. Hepatitis B
 - 1. Treatment
 - 2. Pathogenesis & Natural History
 - II. Hepatitis C
 - 1. Treatment
 - 2. Pathogenesis & Natural History
 - III. Other Hepatitis Viruses
- b) NAFLD, Fibrosis
- c) Other

Public Health

- a) Diagnostics & Epidemiology
 - I. Hepatitis B
 - II. Hepatitis C
- b) Outreach and Linkage to Care
- c) Prevention and Vaccines

Registration Fees

****All fees are in Canadian dollars (CAD) and exclude 13% tax**

Full SUMMIT

	Early Bird	Regular	Onsite
	Until March 1, 2018	March, 2 – June 13, 2018	June 14 – 18, 2018
Delegate	\$795.00	\$895.00	\$995.00
Student / Fellows	\$375.00	\$425.00	\$475.00
Allied Health Professional / Community Organizations	\$495.00	\$595.00	\$695.00
CAHN Special Liver Nurse & Global Hepatitis Summit	\$425.00	\$525.00	\$600.00

Day SUMMIT

	Until March 1, 2018	March, 2 – June 13, 2018	June 14 – 18, 2018
Day Registrations – Friday, June 15, 2018	\$450.00	\$500.00	\$550.00
Day Registrations – Saturday, June 16, 2018	\$450.00	\$500.00	\$550.00
Day Registrations – Sunday, June 17, 2018	\$450.00	\$500.00	\$550.00
CAHN Special Liver Nurse Summit – Thursday, June 14, 2018	\$175.00	\$225.00	\$300.00

General Congress Information

Venue

Metro Toronto Convention Centre, South Building,
222 Bremner Blvd, Toronto, ON M5V 3L9

CME

The Global Hepatitis Summit 2018 is being accredited for Continuing Medical Education (CME) credits. Further information on the number of credits offered will be available on the Symposium website.

Language

The official language of the Congress is English

Registration

Congress registration now open.

Full Congress registration includes:

- Breaks
- Access to the Scientific Program Sessions
- Congress Bag
- Admission to Exhibition
- Summit Opening and Welcome Reception

Contact Us

Congress Secretariat:

GHS2018-info@mci-group.com | +1 416 621 2727

Sponsorship and Exhibition

Meighan Jury

Senior Manager, Strategic Partnerships
meighan.jury@mci-group.com | +1 604 661 4967



www.globalhepatitisummit2018.com



Scientific Program and Call for Abstracts

16th ISVHLD Global Hepatitis Summit
Toronto, Canada | June 14-17, 2018

Collaborating Partners & Symposia

NOHep Village, presented by the WHA

The International Symposium on Viral Hepatitis and Liver Cancer,
presented by AASLD – EASL – ISVHLD

The Pan-American Symposium; Hepatitis Among Indigenous Populations Across
The Americas, presented by AASLD – ALEH – CASL
The Special Liver Nurses Summit, presented by CAHN



www.globalhepatitisummit2018.com

Clinical

Plenary Session: HCV Treatment – Remaining Challenge

Ira Jacobson	Current treatments for HepC – is there anything left to optimize
Michael Manns	Clinical Impact of HCV treatment
Mark Sulkowski	Overcoming current challenges in delivery effective therapy

Plenary Session: Future of HBV Cure

Geoff Dusheiko	Current treatments and definition of cure
Anna Lok	Clinical challenges of evaluating new therapies
Fabien Zoulim	The biological basis of functional cure

HCV Therapy

Gregory Dore	Debate: Acute HCV – to treat or wait?
Xavier Forns	When and how to treat decompensated patients with HCV
Ira Jacobson	Debate: Acute HCV – to treat or wait?
Francesco Negro	Treating HCV outside of the liver: management of extrahepatic manifestations

Long-term Outcomes after HCV SVR

Graham Foster	Will liver transplant disappear for HCV infection?
Michael Fried	Extrahepatic benefits of SVR in HCV infection
Adriaan Van der Meer	How do we prove HCV SVR improves HCC, liver failure and mortality?

New Biomarkers & Endpoints in HBV

Henry L.Y Chan	The value of HBsAg quantification in the natural history and treatment of HBV
Harry L.A Janssen	New biomarkers for HBV infection
Jean Michel Pawlotsky	Choosing the right endpoint for HBV treatment

Starting & Stopping HBV treatment

Adrian Di Bisceglie	Should we treat patients with HBeAg+ infection (immune tolerant)?
Scott Fung	When to start or restart treatment for HBV
Pietro Lampertico	Debate: Can we stop nucleoside analogues before HBsAg loss?
George Papatheodorides	Debate: Can we stop nucleoside analogues before HBsAg loss?

HBV Emerging Therapies

Henry L.Y Chan	New antivirals for HBV treatment – early clinical results
Seng Gee Lim	Is combination or personalized therapy need for success?
Ulrike Protzer	Immunological targets: progress and setbacks

HEV Pathogenesis & Treatment

Shiv Sarin	HEV and emerging worldwide pathogen?
Heiner Wedemeyer	Treatment of HEV infection
TBD	HEV in immunocompromised patients

HDV Pathogenesis & Treatment

Jeffrey Glenn	New developments in testing for HDV infection
Theo Heller	New Treatments for HDV
Heiner Wedemeyer	Current treatments for HDV infection

NASH Treatment & Endpoints

Ariel Feldstein	Pathogenesis of NAFLD
Rohit Loomba	Current assessment and management of NASH
TBD	NASH trial endpoints and emerging therapies

Viral Hepatitis & Transplant

Marina Berenguer	Management of HBV after organ transplantation
Rajender Reddy	Use of HCV infected donors in transplantation?
Gonzalo Sapisoschin	Pushing the envelop: extended criteria for transplantation in HCC

Fibrosis Biomarkers & Treatment

Scott Friedman	Pipeline of anti-fibrotic treatments
TBD	Regression of fibrosis/cirrhosis with antiviral therapy
Keyur Patel	Non-invasive assessment of fibrosis

Clinical Management of HBV

Carla Coffin	Management of HBV in pregnancy
Jordan Feld	How to handle antiviral treatment in immuno-suppressed patients
Jin Lin Hou	Long-term benefits provided by current generation of nucleoside analogues

Public Health

Plenary Session: WHO Elimination Targets

Gregory Dore	National elimination in a focused epidemic: Australia
Manal El-Sayed	National elimination in a generalized epidemic: Egypt
Gottfried Hirnshchall	Elimination targets: rationale and WHO's role in helping countries get there
David Thomas	What tools are needed to generate the evidence – measuring success

The Global Burden of Viral Hepatitis

TBD	The burden and gaps in Africa
Homie Razavi	Global cascade of care for HBV and HCV
John Ward	The burden and gaps in the Americas
TBD	The burden and the gaps in Asia

P.O.C. & Testing Developments

Catharina Boehme	Rolling out new tests in low and middle income countries – 7 country project
Jean Michel Pawlotsky	Challenges & progress with POC and new diagnostics for HBV & HCV
TBD	Using the new tests in difficult-to-reach populations

Elimination Strategies: Microelimination vs National Elimination

Sharon Hutchinson	Micro-elmination – not the best approach – national and global strategies are preferred
Jorge Mera	Cherokee Nation Elimination Project
Mark Thursz	Micro-elimination: addressing one population at a time – an attractive approach

Co-Infections

Marina Klein	Progress towards HCV/HIV elimination
Natasha Martin	What will it take to eliminate HCV/HIV co-infection?
Raymundo Parana	HDV: Epidemiology and control strategies

TasP & Other Prevention Strategies

Margaret Hellard	Treatment as prevention in practice: The Prison Experience
Julio Montaner	Treatment as Prevention: Lessons from HIV
TBD	Harm Reduction in the context of the North American opiate epidemic

Control Strategies in Special Populations

Christina Greenaway	The migrant crisis: A challenge for elimination efforts?
Shruti Mehta	Control strategies in PWID
TBD	Role of community in the global response

Vaccination in HAV/HEV/HBV

Homie Razavi	Should changing epidemiology change HAV vaccination policy?
Eyasu Teshale	HEV vaccination strategies – outbreak control vs routine vaccination
Mark Thursz	HBV vaccination – Is the birth dose the Achilles heel to success?

Economics of HBV & HCV Therapy

Andrew Hill	How low will the prices go?
Giten Khwairakpam	Overcoming IP, pricing and other barriers to access
TBD	Beyond the drug prices: The economics of addressing viral hepatitis

Linkage to Care in Viral Hepatitis

Jason Grebley	Engaging the hard-to-reach – is there evidence on what is working?
Mel Krajden	National screening approaches – not one size fits all
Maud Lemoine	Linkage to care in low-middle income countries – strategies and data

Basic Science

Plenary Session: Immune Regulation in Viral Hepatitis

Andrea Cox	Immunological adaptation to repeated HCV exposure
Carlo Ferrari	Powering antiviral T cell function in chronic viral infection
Barbara Rehermann	Regulation of immunity in the era of successful HCV therapy

HCV Virology

Ralf Bartenschlager	HCV virion production and assembly
Thomas Baumert	HCV infection and entry
Jane McKeating	Physiological regulation of HCV Replication

HCV Immunology & Vaccine

Michael Houghton	Progress towards a prophylactic HCV vaccine
Georg Lauer	Systems biology approaches to understanding T cell immunity in HCV
TBD	Immunological mechanisms of spontaneous HCV clearance

HBV Virology

Massimo Levrero	Maintenance and activity of HBV cccDNA
Wenhui Li	Defining the steps of HBV entry from patients to cell culture
TBD	HBV DNA integration and its impact on the natural history of disease

HBV Immunology

Antonio Bertoletti	HBV-specific T cell immunity vs. virological control in chronic HBV infection
Adam Gehring	Monocyte and DC function in chronic HBV and their role in immunomodulatory therapy
Robert Thimme	Negative regulators of HBV-specific T cell function

HBV Preclinical Therapy Targets

Christoph Seeger	Emerging strategies to target HBV cccDNA
John Tavis	Preclinical viral and host targets for HBV therapy (not cccDNA)
TBD	Advances in HBV entry inhibitors targeting the NTCP receptor

HAV/HDV//HEV Virology

Eui-Cheol Shin	HAV infection, replication and susceptibility to immune control
Camille Sureau	Intracellular interplay between HDV and HBV and the impact on viral replication
TBD	Diversity and replication of HEV

Viral Hepatitis Models

Maura Dandri	Humanized mice for the study of HBV and HDV infection
Alex Ploss	Humanized mice for the study of HCV and HEV infection
Lorne Tyrell	Cell culture infection models to study viral hepatitis

Hepatocyte Culture & Generation

Gordon Keller	Human hepatocytes from embryonic stem cells: comparison to primary hepatocytes
TBD	Generation of hepatocytes from induced pluripotent stem cells permissible to hepatitis virus infection
TBD	Culture and maintenance of primary human hepatocytes

Liver Inflammation & Fibrogenesis

Ariel Feldstein	Mechanisms and consequences of hepatocyte cell death during liver disease
Scott Friedman	Regulation of fibrogenesis by stellate cells in liver disease
Yujin Hoshida	Mechanisms of carcinogenesis in the cirrhotic liver